Abstract Details

Title Marked Cervical and Thoracic Spinal Cord Volumetric Reduction in HAM/TSP Revealed by 3T MRI

Topic Infections/AIDS/Prion Disease

Presentation(s) P06 - (-)

Poster/Presentation
Number 178

Objective

Background BACKGROUND: HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic inflammatory disabling disease associated with HTLV-I infection. Post-mortem pathology analysis revealed progressive spinal cord gliosis and atrophy, but in vivo Magnetic Resonance Imaging (MRI) quantification has been poorly studied.

Design/Methods DESIGN/METHODS: A cross-sectional study performed at Instituto de Pesquisa Clinica Evandro Chagas/FIOCRUZ and D'Or Institute for Research and ��ɫ��, Rio de Janeiro, Brazil, from September, 2011 to October, 2012. Fifteen HAM/TSP patients (39.5± 9.7 y/o, mean ± sd), categorized according to their disability level, and 12 healthy controls (35.7± 6.9 y/o, mean ± sd) were enrolled in a clinical and MRI protocol (3T Philips scanner), including a cervical (C2-C3 levels) and a thoracic (T5-T6 levels) spinal cord axial T2 3D gradient-echo sequences. Post-processing of the acquired volumetric data was performed with MRIcroN software. Spinal cord volumes were compared using a linear regression model after adjustment for age and gender.

Results RESULTS: Volumes were reduced in patients compared to controls in cervical (2325 ± 300 mm3 and 2992 ± 172 mm3, mean ± sd) and thoracic spinal cord (1085 ± 183 mm3 and 1636 ± 142, mean ± sd), (p < .0001). Preliminary analysis did not show significant association between the disability level and mean cervical or thoracic spinal cord volumes.

Conclusions CONCLUSIONS: Spinal cord MRI volumetry may be a promising tool to discriminate HAM/TSP patients from healthy controls. The association between spinal cord volumes and HAM/TSP patients' disability level deserves further evaluation in larger samples.

Authors/Disclosures
PRESENTER	No disclosure on file
Abelardo Q. Araujo, MD, PhD, MSc (Oswaldo Cruz Foundation / The Federal University of Rio De Janeiro)	No disclosure on file
	No disclosure on file
Marco A. De Lima, MD	No disclosure on file
Daniel D. Bezerra, MD	No disclosure on file
Felipe Schmidt	Felipe Schmidt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Felipe Schmidt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Felipe Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novatis. Felipe Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Felipe Schmidt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology)	The institution of Dr. Wildemann has received research support from Roche. The institution of Dr. Wildemann has received research support from Novartis. The institution of Dr. Wildemann has received research support from Argenx. Dr. Wildemann has received personal compensation in the range of $500-$4,999 for serving as a Conference participant with Neuraxpharm. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Soeaker with Instand.
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��